LGC acquires The Native Antigen Company, strengthening its offer to the IVD sector

Today, LGC announced the acquisition of The Native Antigen Company (NAC), one of the world’s leading suppliers of high quality infectious disease antigens and antibodies.

NAC is a developer, manufacturer and supplier of critical reagents to the in vitro diagnostic (IVD), pharmaceutical and academic sectors. It offers a comprehensive portfolio of native and recombinant infectious disease antigens and related products including pathogen receptors, virus-like particles and antibodies for use in immunoassay applications, vaccine development and quality control solutions. NAC was one of the first companies globally to offer antigens for SARS-COV-2 and continues to play an important role in supporting the global response to the COVID-19 pandemic.

The acquisition strengthens LGC’s existing product offering to the IVD sector, which includes a range of quality assurance tools, immunoassay reagents and disease state plasma as well as probes and primers for molecular diagnostics.

NAC is a natural fit with our clinical diagnostics business and will enable us to provide an expanded portfolio of critical reagents to our customers. NAC’s focus on infectious disease is highly complementary with our existing offer to this segment comprising controls, reference materials, MDx tools and other components. We are excited to welcome our new colleagues into our organisation.”

Michael Sweatt, Executive Vice President and General Manager, Clinical Diagnostics, LGC

We are delighted to be joining LGC as an integral part of their fast growing clinical diagnostics business. Even more so, we are excited to join such a well-respected organisation that shares our purpose and mission, and that will support our diagnostic customers by providing even more world-leading products and services.”

Nick Roesen, COO, NAC

Formed in 2010, NAC is based in Oxford, UK and currently employs over 30 people. It maintains an ISO 9001 accreditation.

NAC’s portfolio includes more than 60 viral and infectious disease products, with strengths in Dengue, Cytomegalovirus, Zika, Chikungunya and Clostridium difficile (C. diff).

Source:

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
COVID-19 patient with repeatedly undetectable SARS-CoV-2 antibodies